Announces Launch of Licensing Partnership with Oklahoma Based Clinic
Summary
TORONTO, CANADA, April 03, 2024 Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (Awakn or the Company) a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the launch of an additional Licensing Partnership agreement in North America. Lane Peyton commented The Rivus Wellness and Research Institute has consistently served the Oklahoma City mental health community with innovative treatments, interventions, and preventions, and we feel that this partnership with Awakn Kare will benefit our patients tremendously. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercializing our R&D pipeline across multiple channels.Rivus Wellness and Research Institute is a team of medical and scientific professionals who are united by a passion for individual and community health. Often, but not always, forward-looking statements can be identified by the use of words such as plans, expects, is expected, budget, scheduled, estimates, continues, forecasts, projects, predicts, intends, anticipates, targets or believes, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", would, should, might or will be taken, occur or be achieved, including statements relating the business of the Company. These include, but are not limited to: fluctuations in general macroeconomic conditions; the business plans and strategies of the Company; the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; fluctuations in securities markets; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; expectations regarding the size of the addiction market; and regulatory or political change.